Histone deacetylase inhibitor (HDACI)–induced thrombocytopenia (TCP) is a major dose-limiting
toxicity of this new class of drugs. Using preclinical models to study the molecular and …

Over the last 5 years, a plethora of histone deacetylase inhibitors (HDACi) have been evaluated
in clinical trials. These drugs have in common the ability to hyperacetylate both histone …

The deacetylase inhibitors are a structurally diverse class of targeted antineoplastic agents
that have demonstrated in vitro and in vivo preclinical activity in a wide range of malignancies…

Histone deacetylase inhibitors (HDACi) are a new class of antineoplastic agents with
demonstrable preclinical antitumor activity in both in vitro and in vivo studies in a wide range of …

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical
activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 …

Enteropathy‐associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease,
with a poor prognosis due to perforation and gastro‐intestinal bleeding during treatment…

… Bishton, Mark; Nottingham University Hospitals, Haematology Department … Adam Al-Hakim1*,
James A Poulter2*, Dina Mahmoud1, Ailsa MS Rose1, Suzanne Elcombe3, Helen …

Central nervous system (CNS) relapse following R‐CHOP (rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B‐cell …

The recently devised National Comprehensive Cancer Network International Prognostic
Index ( NCCN ‐ IPI ) appears superior to the revised IPI (R‐ IPI ) in delineating outcome in …

There are few treatment options for patients with Hodgkin Lymphoma (HL) who relapse after
conventional therapies. Panobinostat is an orally available pan deacetylase inhibitor with …